JPWO2022047244A5 - - Google Patents

Info

Publication number

JPWO2022047244A5

JPWO2022047244A5 JP2023513678A JP2023513678A JPWO2022047244A5 JP WO2022047244 A5 JPWO2022047244 A5 JP WO2022047244A5 JP 2023513678 A JP2023513678 A JP 2023513678A JP 2023513678 A JP2023513678 A JP 2023513678A JP WO2022047244 A5 JPWO2022047244 A5 JP WO2022047244A5

Authority

JP

Japan

Prior art keywords

individual

cyclodextrin

hydroxypropyl

amount

cholesterol

Prior art date

2024-08-27

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 80
• 239000013078 crystal Substances 0.000 claims 41
• 235000012000 cholesterol Nutrition 0.000 claims 40
• ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims 34
• 208000007536 Thrombosis Diseases 0.000 claims 19
• 208000007413 cholesterol embolism Diseases 0.000 claims 17
• 230000002792 vascular Effects 0.000 claims 13
• 230000002526 effect on cardiovascular system Effects 0.000 claims 10
• 208000014674 injury Diseases 0.000 claims 10
• 230000008733 trauma Effects 0.000 claims 10
• 238000000034 method Methods 0.000 claims 7
• 239000008194 pharmaceutical composition Substances 0.000 claims 7
• 238000001990 intravenous administration Methods 0.000 claims 4
• 210000002966 serum Anatomy 0.000 claims 4
• 208000024891 symptom Diseases 0.000 claims 4
• WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 3
• 210000004369 blood Anatomy 0.000 claims 3
• 239000008280 blood Substances 0.000 claims 3
• NJWCVQBHNBLNOZ-ZRMYETLXSA-N (1S,3R,5R,6S,8R,10R,11S,13S,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,47R,48S,49R)-5,20,30,35-tetrakis(hydroxymethyl)-49-(2-hydroxypropoxy)-10,15,25-tris(2-hydroxypropoxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,37,38,39,40,41,42,43,44,45,47,48-dodecol Chemical compound CC(O)COC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@@H]6[C@@H](COCC(C)O)O[C@H](O[C@@H]7[C@@H](CO)O[C@H](O[C@@H]8[C@@H](COCC(C)O)O[C@H](O[C@H]1C[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](OCC(C)O)[C@H]3O NJWCVQBHNBLNOZ-ZRMYETLXSA-N 0.000 claims 2
• IOWMKBFJCNLRTC-XWXSNNQWSA-N (24S)-24-hydroxycholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@H](O)C(C)C)[C@@]1(C)CC2 IOWMKBFJCNLRTC-XWXSNNQWSA-N 0.000 claims 2
• FYHRJWMENCALJY-YSQMORBQSA-N (25R)-cholest-5-ene-3beta,26-diol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCC[C@H](CO)C)[C@@]1(C)CC2 FYHRJWMENCALJY-YSQMORBQSA-N 0.000 claims 2
• IOWMKBFJCNLRTC-UHFFFAOYSA-N 24S-hydroxycholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(O)C(C)C)C1(C)CC2 IOWMKBFJCNLRTC-UHFFFAOYSA-N 0.000 claims 2
• DKISDYAXCJJSLZ-UHFFFAOYSA-N 26-Hydroxy-cholesterin Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(CO)C)C1(C)CC2 DKISDYAXCJJSLZ-UHFFFAOYSA-N 0.000 claims 2
• 101150092476 ABCA1 gene Proteins 0.000 claims 2
• 108700005241 ATP Binding Cassette Transporter 1 Proteins 0.000 claims 2
• 102100022594 ATP-binding cassette sub-family G member 1 Human genes 0.000 claims 2
• 229920000858 Cyclodextrin Polymers 0.000 claims 2
• 108010090314 Member 1 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 claims 2
• 102100033616 Phospholipid-transporting ATPase ABCA1 Human genes 0.000 claims 2
• 239000008186 active pharmaceutical agent Substances 0.000 claims 2
• 239000003146 anticoagulant agent Substances 0.000 claims 2
• 238000001802 infusion Methods 0.000 claims 2
• 108020004999 messenger RNA Proteins 0.000 claims 2
• 239000000546 pharmaceutical excipient Substances 0.000 claims 2
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 2
• 230000009885 systemic effect Effects 0.000 claims 2
• 208000024172 Cardiovascular disease Diseases 0.000 claims 1
• 208000021479 Cardiovascular injury Diseases 0.000 claims 1
• 206010053567 Coagulopathies Diseases 0.000 claims 1
• 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
• 206010020772 Hypertension Diseases 0.000 claims 1
• 206010061218 Inflammation Diseases 0.000 claims 1
• -1 Trappsol® CycloTM Chemical compound 0.000 claims 1
• 229940127219 anticoagulant drug Drugs 0.000 claims 1
• 208000007474 aortic aneurysm Diseases 0.000 claims 1
• 208000015294 blood coagulation disease Diseases 0.000 claims 1
• 238000013130 cardiovascular surgery Methods 0.000 claims 1
• 230000009852 coagulant defect Effects 0.000 claims 1
• 206010012601 diabetes mellitus Diseases 0.000 claims 1
• 230000004054 inflammatory process Effects 0.000 claims 1
• 238000002560 therapeutic procedure Methods 0.000 claims 1
• 230000002537 thrombolytic effect Effects 0.000 claims 1